Bluesky Facebook Reddit Email

Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer

06.30.24 | Compuscript Ltd

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0015

Announcing a new publication for Acta Materia Medica journal. Elevated cellular oxidative stress is a common marker of cancer cell dysregulation caused by malignant transformation.

Thioredoxin reductase (TrxR, encoded by TXNRD ) is a crucial enzyme that regulates cellular oxidative stress and the survival of many types of cancer cells. Therefore, targeting TrxR may lead to selective cell death in cancer cells. Pristimerin, a plant triterpenoid, increases the accumulation of reactive oxygen species (ROS) in cells, but its specific regulatory mechanism is unclear. The authors of this article found that pristimerin selectively targets TrxR and subsequently induces apoptosis in human non-small cell lung cancer cells, and inhibits tumor growth in vivo with low toxicity to normal cells. Pristimerin was found to inhibit cancer cell growth primarily by inhibiting cellular TrxR, thereby compromising TrxR’s antioxidant function in cells and resulting in the accumulation of oxidized Trx. Furthermore, excessive ROS accumulation stimulated by pristimerin triggered tumor-specific amplification of oxidative stress in cancer cells and ultimately led to targeted destruction of cancer cells.

This data may support the development of potential therapeutic molecules as selective anticancer agents targeting highly enriched TrxR in cancer cells.

# # # # # #

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed

Queries about the journal can be sent to editorialoffice@amm-journal.org .

Please visit https://amm-journal.org/ to learn more about the journal.

Editorial Board: https://amm-journal.org/index.php/editorial-board/

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal ; Facebook ( https://www.facebook.com/AMMjournal )

eISSN 2737-7946

Yajun Chu, Qianhe Xu and Xiedong Zhou et al. Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer. Acta Materia Medica. 2024. Vol. 3(2):239-253. DOI: 10.15212/AMM-2024-0015

Acta Materia Medica

10.15212/AMM-2024-0015

Keywords

Article Information

Contact Information

Conor Lovett
Compuscript Ltd
c.lovett@cvia-journal.org

How to Cite This Article

APA:
Compuscript Ltd. (2024, June 30). Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer. Brightsurf News. https://www.brightsurf.com/news/L3R5D568/pristimerin-inhibits-thioredoxin-reductase-in-the-treatment-of-non-small-cell-lung-cancer.html
MLA:
"Pristimerin inhibits thioredoxin reductase in the treatment of non-small cell lung cancer." Brightsurf News, Jun. 30 2024, https://www.brightsurf.com/news/L3R5D568/pristimerin-inhibits-thioredoxin-reductase-in-the-treatment-of-non-small-cell-lung-cancer.html.